Current Month 2013
Article Features
  Body Mass Index Associated with Cancer, Regardless of Body Shape
Breast Cancer Patients Place Huge Emphasis on Gene Expression Profiling Tests
Breast Cancer Replicates Brain Development Process
Cancer Stem Cells Linked to Drug Resistance
Experimental Blood Test Spots Recurrent Breast Cancers and Monitors Response to Treatment
False-Positive Mammogram Anxiety has Limited Impact on Women's Well-Being
Genetic Link Discovered to Difficult-to-Diagnose Breast Cancer Subtype
Gold Nanoparticles Help Target, Quantify Breast Cancer Gene Segments in a Living Cell
Lymph Node Ultrasounds More Accurate in Obese Breast Cancer Patients
New Study Helps to Explain Why Breast Cancer Often Spreads to the Lung
Physicist Creates New Nanoparticle for Cancer Therapy
Promising New Approach Targets Cancer Protein to Slow Tumor Growth
Scientists Find Way to Target Cells Resistant to Chemo
Shared Decision Making During Radiation Improves Patient Satisfaction
Study Highlights New Drug, Molecular Insight Into Triple-Negative Breast Cancer
Surgeons and Health Care Settings Influence Type of Breast Cancer Surgery Women Undergo
Surprising New Insights into the PTEN Tumor Suppressor Gene
Tumor-Suppressor Connects with Histone Protein to Hinder Gene Expression
Unemployment Common After Breast Cancer Treatment
Virus-Fighting Genes Linked to Mutations in Cancer
Vitamin D May Raise Survival Rates Among Cancer Patients


Experimental Blood Test Spots Recurrent Breast Cancers and Monitors Response to Treatment

Johns Hopkins Kimmel Cancer Center investigators report they have designed a blood test that accurately detects the presence of advanced breast cancer and also holds promise for precisely monitoring response to cancer treatment.

The test, called the cMethDNA assay, accurately detected the presence of cancer DNA in the blood of patients with metastatic breast cancers up to 95 percent of the time in laboratory studies. The findings were described in the journal Cancer Research.

Currently, there is no useful laboratory test to monitor patients with early stage breast cancer who are doing well, but could have an asymptomatic recurrence, says Saraswati Sukumar, Ph.D., who is the Barbara B. Rubenstein Professor of Oncology and co-director of the Breast Cancer Program at the Johns Hopkins Kimmel Cancer Center. Generally, radiologic scans and standard blood tests are indicated only if a woman complains of symptoms, such as bone aches, shortness of breath, pain, or worrisome clinical exam findings. Otherwise, routine blood tests or scans in asymptomatic patients often produce false positives, leading to additional unnecessary tests and biopsies, and have not been shown to improve survival outcomes in patients with early stage breast cancer who develop a recurrence.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon